| Autor: |
Corvino S; Department of Neurosciences, Reproductive and Odontostomatological Sciences, Neurosurgical Clinic, School of Medicine, Università di Napoli 'Federico II', 80131 Naples, Italy., Somma T; Department of Neurosciences, Reproductive and Odontostomatological Sciences, Neurosurgical Clinic, School of Medicine, Università di Napoli 'Federico II', 80131 Naples, Italy., Certo F; Department of Neurosciences, Division of Neurosurgery, Policlinico 'G. Rodolico-S. Marco', University Hospital, 95123 Catania, Italy., Bonomo G; Department of Neurosciences, Division of Neurosurgery, Policlinico 'G. Rodolico-S. Marco', University Hospital, 95123 Catania, Italy., Grasso E; Department of Neurosciences, Division of Neurosurgery, Policlinico 'G. Rodolico-S. Marco', University Hospital, 95123 Catania, Italy., Esposito F; Department of Neurosciences, Reproductive and Odontostomatological Sciences, Neurosurgical Clinic, School of Medicine, Università di Napoli 'Federico II', 80131 Naples, Italy., Berardinelli J; Department of Neurosciences, Reproductive and Odontostomatological Sciences, Neurosurgical Clinic, School of Medicine, Università di Napoli 'Federico II', 80131 Naples, Italy., Barbagallo G; Department of Neurosciences, Division of Neurosurgery, Policlinico 'G. Rodolico-S. Marco', University Hospital, 95123 Catania, Italy. |
| Abstrakt: |
Ollier disease (OD), acute myeloid leukemia (AML), and brain glioma (BG) are three apparently completely different neoplasms in terms of histopathology, clinic, natural history, and management, but they can affect the same patient. This study aimed to identify the common molecular pathways involved in the pathogenesis of all three diseases and discuss their current and potential role as therapeutic targets. A detailed and comprehensive systematic literature review according to PRISMA guidelines on OD patients harboring BG and/or AML was made. In addition, the unique case of a patient affected by all three considered diseases has been added to our case series. Demographic, pathological, treatment, and outcome data were analyzed and discussed, mainly focusing on the molecular findings. Twenty-eight studies reported thirty-three patients affected by OD and BG, and only one study reported one patient with OD and AML, while only our patient harbored all three pathologies. The IDH R132H mutation was the only genetic alteration shared by all three pathologies and was simultaneously detected in enchondromas and brain glioma in 100% (3/3) of OD patients with BG and also in the neoplastic blood cells of the single patient hosting all three diseases. The IDH1-R132H gene mutation is the etiopathogenetic common denominator among three apparently different tumors coexisting in the same patient. The adoption of mutant-specific IDH1 inhibitor molecules could represent a potential panacea for these conditions in the era of targeted therapies. Further studies with larger clinical series are needed to confirm our results and hypothesis. |
